Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.57 |
| ▸ | MTOR | P42345 | 14/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.53 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.53 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328139 | 0.87 | PIK3CA (0.62) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL855455 | 0.86 | PIK3CA (0.65) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL10198065 | 0.85 | MTOR (0.61) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL15014988 | 0.81 | PIK3CA (0.54) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL855340 | 0.80 | MTOR (0.76) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL856068 | 0.78 | MTOR (0.58) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL10327593 | 0.77 | PIK3CA (0.59) | PIK3CAMTORPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL10327586 | 0.75 | PIK3CA (0.71) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL3994331 | 0.75 | PIK3CA (0.58) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL856762 | 0.75 | PIK3CA (0.52) | PIK3CAMTORPIK3CBPIK3CGAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | PIK3CA 5/4885MTOR 64/4885PIK3CB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.